Pyridorin: Completed Phase IIb enrollment

NephroGenex completed enrollment of 317 patients in a double-blind, international Phase IIb trial (PYR-210) comparing 150 and 300 mg oral Pyridorin pyridoxamine given twice daily vs. placebo for 1 yea...